Arca
Skip to content
Tools
Tools

Alopecia areata

Drug research and approvals for alopecia areata: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 89 studies of alopecia areata are recruiting on ClinicalTrials.gov, Health Canada has authorized 22 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 89
  • Trials authorized in Canada: 22
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 89 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 7

Phase 2 12 of 21

Phase 1 or earlier 11

How its trials ended

457 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 86 whose ending is known, 44% met their primary endpoint, 3% missed it and 52% stopped early.

  • Completed, result not reported18240%
  • Ongoing12126%
  • Status unknown6815%
  • Met its primary endpoint388%
  • Stopped: other or unclear286%
  • Stopped: enrollment or feasibility72%
  • Stopped: sponsor or business decision61%
  • Stopped: lack of efficacy41%
  • Missed its primary endpoint31%

Trials authorized in Canada

The 10 newest of 22; search them all in Canada trials
Apr 15, 2026A phase 2, randomized, multicenter, double-blind, placebo-controlled proof of concept study to investigate efficacy and safety of LY4005130 in adult…LY4005130Eli LillyOngoing
Aug 15, 2025A double-blind, randomized, placebo-controlled multicenter study to evaluate the efficacy and safety of deuruxolitinib in adolescent patients with severe…Deuruxolitinib (CTP-543)Sun Pharmaceutical IndustriesOngoing
Jun 25, 2025A phase 3 randomized, double-blind, placebo-controlled study to investigatethe efficacy and safety of ritlecitinib in pediatric participants 6 to less than 12…Ritlecitinib (PF-06651600)PfizerClosed
Jun 13, 2025A phase 2a, randomized, double-blind, placebi-controlled, proof-of-concept trial with part b open-label extension of ADX-914 for the treatment of severe…ADX-914Q32 Bio IncOngoing
Jan 10, 2025A phase 1b/2a, intraindividual study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ALD-102 solution for intradermal…ALD-102Aldena Therapeutics (Uk), Ltd.Ongoing
May 8, 2024A phase 2, randomized, double-blind, placebo-controlled, parallel group, 3- arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy…Amlitelimab (SAR445229)Sanofi-Aventis Canada IncClosed
Jan 30, 2024A phase 2b, randomized, double-blind, parallel group, placebo-controlled 60- week study to evaluate the efficacy and safety of rezpegaldesleukin in treatment…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsOngoing
Nov 6, 2023A phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe…Upadacitinib (ABT-494)AbbVieOngoing
Aug 9, 2023A phase 1b/2a study to evaluate the safety, pharmacokinetics and efficacy of IMG-007 in adult alopecia areata participants with 50% or greater scalp hair lossIMG-007Inmagene LLCClosed
Jun 15, 2023A phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of baricitinib in children from 6 years to…Baricitinib (LY3009104)Eli LillyOngoing

FDA orphan designations

Approved first, then open designations, newest first
Dec 21, 2017Trafermin in combination with plasma and platelet rich…Treatment of alopecia areata in pediatric patientsHCell, Inc.Designated
Jun 13, 2003DiphenylcyclopenoneTreatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])Lloyd E. King, Jr.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 15, 2023LitfuloRitlecitinibPfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.